Notice2023-08637
National Institute on Drug Abuse; Notice of Meeting
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
April 25, 2023
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 79 (Tuesday, April 25, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 79 (Tuesday, April 25, 2023)]
[Notices]
[Pages 25001-25002]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-08637]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the National Advisory
Council on Drug Abuse.
The meeting will be open to the public, as indicated below, with
attendance limited to space available. Individuals who plan to attend
as well as those who need special assistance, such as sign language
interpretation or other reasonable accommodations, should notify Dr.
Gillian Acca via email at <a href="/cdn-cgi/l/email-protection#84e3ede8e8ede5eaaae5e7e7e5c4eaedecaae3ebf2"><span class="__cf_email__" data-cfemail="c6a1afaaaaafa7a8e8a7a5a5a786a8afaee8a1a9b0">[email protected]</span></a> five days in advance of
the meeting. The open session will be videocast and can be accessed
from the NIH Videocasting and Podcasting website (<a href="https://videocast.nih.gov/">https://videocast.nih.gov/</a>).
A portion of the meeting will be closed to the public in accordance
with the provisions set forth in sections 552b(c)(4) and 552b(c)(6),
Title 5 U.S.C., as amended. The grant applications and the discussions
could disclose confidential trade secrets or commercial property such
as patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Advisory Council on Drug Abuse.
Date: May 9, 2023.
Closed: 10:30 a.m. to 11:45 a.m.
Agenda: To review and evaluate grant applications.
Open: 12:45 p.m. to 5:00 p.m.
Agenda: Presentations and other business of the Council.
Place: Rockledge II, Conference Room 270 A/B, National
Institutes of Health, National Institute on Drug Abuse, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Susan R.B. Weiss, Ph.D., Director, Division of
Extramural Research, Office of the Director, National Institute on
Drug Abuse, NIH, Three White Flint North, RM 09D08, 11601 Landsdown
Street, Bethesda, MD 20852, 301-443-6480, <a href="/cdn-cgi/l/email-protection#9fece8faf6ececdff1f6fbfeb1f1f6f7b1f8f0e9"><span class="__cf_email__" data-cfemail="364541535f454576585f525718585f5e18515940">[email protected]</span></a>.
Any interested person may file written comments with the committee
by forwarding the statement to Dr. Gillian Acca via email at
<a href="/cdn-cgi/l/email-protection#cdaaa4a1a1a4aca3e3acaeaeac8da3a4a5e3aaa2bb"><span class="__cf_email__" data-cfemail="57303e3b3b3e3639793634343617393e3f79303821">[email protected]</span></a>. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has procedures at <a href="https://www.nih.gov/about-nih/visitor-information/campus-access-security">https://www.nih.gov/about-nih/visitor-information/campus-access-security</a> for
entrance into on-campus and off-campus facilities. All visitor
vehicles, including taxicabs, hotel, and airport shuttles will be
inspected before being allowed on campus. Visitors attending a meeting
on campus or at an off-campus federal facility will be asked to show
one form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their visit.
Additional Health and Safety Guidance: Before attending a meeting
at an NIH facility, it is important that visitors review the NIH COVID-
19 Safety Plan at <a href="https://ors.od.nih.gov/sr/dohs/safety/NIH-covid-19-safety-plan/Pages/default.aspx">https://ors.od.nih.gov/sr/dohs/safety/NIH-covid-19-safety-plan/Pages/default.aspx</a> for information about requirements and
procedures for entering NIH facilities, especially when COVID-19
community levels are medium or high. In addition, the Safer Federal
Workforce website has FAQs for visitors at <a href="https://www.saferfederalworkforce.gov/faq/visitors/">https://www.saferfederalworkforce.gov/faq/visitors/</a>. Please note that if an
individual has a COVID-19 diagnosis within 10 days of the meeting, that
person must attend virtually. (For more information please read NIH's
Requirements for Persons after Exposure at https://ors.od.nih.gov/sr/
dohs/safety/
[[Page 25002]]
NIH-covid-19-safety-plan/COVID-assessment-testing/Pages/persons-after-
exposure.aspx and What Happens When Someone Tests Positive at <a href="https://ors.od.nih.gov/sr/dohs/safety/NIH-covid-19-safety-plan/COVID-assessment-testing/Pages/test-positive.aspx">https://ors.od.nih.gov/sr/dohs/safety/NIH-covid-19-safety-plan/COVID-assessment-testing/Pages/test-positive.aspx</a>.) Anyone from the public
can attend the open portion of the meeting virtually via the NIH
Videocasting website (<a href="http://videocast.nih.gov">http://videocast.nih.gov</a>). Please continue
checking these websites, in addition to the committee website listed
below, for the most up to date guidance as the meeting date approaches.
Information is also available on the Institute's/Center's home
page: <a href="http://www.drugabuse.gov/NACDA/NACDAHome.html">www.drugabuse.gov/NACDA/NACDAHome.html</a>, where an agenda and any
additional information for the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: April 19, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-08637 Filed 4-24-23; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on April 25, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.